Karen M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 6,471 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the completion of the transaction, the insider now directly owns 54,322 shares in the company, valued at $915,868.92. The trade was a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded up $1.19 during mid-day trading on Friday, hitting $19.03. 1,506,964 shares of the company's stock were exchanged, compared to its average volume of 556,728. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $19.09. The stock's 50-day simple moving average is $16.77 and its 200-day simple moving average is $15.40. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in shares of Centessa Pharmaceuticals by 4.6% in the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after buying an additional 129,300 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Centessa Pharmaceuticals by 54.1% during the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after purchasing an additional 953,659 shares during the last quarter. Franklin Resources Inc. lifted its stake in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after purchasing an additional 1,145,823 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $20,698,000. Finally, Baker BROS. Advisors LP increased its stake in shares of Centessa Pharmaceuticals by 123.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company's stock valued at $19,623,000 after purchasing an additional 677,966 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CNTA. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.